A skilled & strong team

Founder, President and CEO

Ceres' President and CEO, Dr. Thomas Joudinaud, is a former cardiovascular and thoracic surgeon (MD) holding a PhD in pharmacology from the University of Montana. Over the past 14 years, he has served as a Pharma Strategy consultant, contributing to market assessments and development plans for products in rare diseases. Thomas has excelled in portfolio reviews, resource allocation for leading pharmaceutical companies, and the evaluation of business plans, price potential, and sales forecasts for products in development. His collaborative ventures include prestigious pharma consulting firms like The Boston Consulting Group and AEC Partners.

Thomas possesses an extensive business and investor network and additionally serves as a Board member at Osivax, a clinical-stage vaccine Biotech.

Founder, General Manager and COO

Henri Bénech is a former researcher specializing in drug metabolism and pharmacokinetics. He served as the founder and leader of a pharmacological platform providing advisory services to the pharmaceutical industry at the French Alternative Energies and Atomic Energy Commission (CEA). In 2012, Henri transitioned into a business development role in Life Sciences at the CEA. He worked as a rapporteur at the French committee negotiating the prices of medicines (CEPS) for a period of five years gaining an expertise in medicines pricing.

Henri is a distinguished member of the French National Academy of Pharmacy and holds the position of co-founder and board member at Skymab Biotherapeutics.

Founder and Chief Scientific Advisor

Aloïse Mabondzo, PhD, Research director at CEA, expert in neuropharmacology, neuroinflammation and blood brain barrier physiopathology. After his PhD thesis in virology at the CEA (Life sciences Division), Aloïse started research in the field of experimental modeling of the human blood-brain barrier, precision medicine through the modeling of pathological brain organoids, translational research on metabolic and tumoral brain pathologies. He therefore created the Laboratory of neurovascular unity study and therapeutic innovation.

Aloïse is co-author of more than 70 publications in peer-reviewed scientific journals and also of 7 patents. He is the Scientific Director of Ceres Brain.

CMO

Dr. Jean-Louis Pinquier, a graduate in Medicine from Paris, holds a Doctor of Medicine degree and possesses extensive expertise in clinical development, particularly in the neurology domain, with a distinguished career spanning over 20 years at Sanofi. Following his tenure at Sanofi, Jean-Louis has taken on various roles as a consultant and advisor, providing his expertise to numerous pharmaceutical companies. Additionally, he has contributed his insights to Medicen, the competitiveness cluster in the Paris area, showcasing his continued commitment to advancing the pharmaceutical and healthcare sectors.

Pharmaceutical Development Director

Graduate from the chemical engineering school ENSIACET (Toulouse, France) and holds a PhD in Chemistry (Nice Sophia-Antipolis, France). With more than 15 years of experience in drug development, especially in CMC, she participated in to the development, from early phase to phase 3, of various therapeutics in biotech companies such as Neovacs and DBV Technologies. Camille joined the company in October 2024

Research director, expert in Amyotrophic Lateral Sclerosis

Neurologist, Neurodegenerative Diseases

Neurologist, Amyotrophic Lateral Sclerosis

Pediatrics and Biochemistry

Formulation and Industrialization

Consultant, Toxicology

Founder and Consultant Chemistry

Consultant, Biostatistic

Consultant, Microbiology

Consultant, Strategic Regulatory

Senior consultant in Life Sciences

Consultant CMC

Former CEO of Amylyx France, Consultant in Public Affairs and BD

Global Optimization Director - International Business Unit at Pierre Fabre Group

Founder, President and CEO

Founder, General Manager and COO

CFO Greater China at Sanofi
French Foreign Trade Advisor

Managing Director & Partner at Boston Consulting Group (BCG)